HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients ; volume:38 ; number:3 ; day:15 ; month:2 ; year:2021 ; pages:1690-1700 ; date:3.2021
Advances in therapy ; 38, Heft 3 (15.2.2021), 1690-1700, 3.2021
- Creator
-
Morgan, Jake R.
Savinkina, Alexandra
Pires dos Santos, Ana Gabriela
Xue, Zhenyi
Shilton, Sonjelle
Linas, Benjamin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01647-4
- URN
-
urn:nbn:de:101:1-2021041814214384764805
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morgan, Jake R.
- Savinkina, Alexandra
- Pires dos Santos, Ana Gabriela
- Xue, Zhenyi
- Shilton, Sonjelle
- Linas, Benjamin
- SpringerLink (Online service)
Other Objects (12)
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment